Cancer Biomarker Prospects May Be Unrealistic, At Least For Now
The high hopes for genomics and proteomics research to yield valid cancer biomarkers may exceed the field's current capabilities, David Ransohoff (University of North Carolina) cautioned at the Institute of Medicine's National Cancer Policy Forum
You may also be interested in...
FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16
As part of a strategy to encourage biomarker qualification, FDA is prepared to issue guidances on the use of specific biomarkers
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011